Table 6.
Target quality gap outcomes over three PDSA cycles during the intervention period (18 September 2019 and 17 March 2020).
| Target quality gap | Cycle A (18 Sept to 24 Nov) |
Cycle B (25 Nov to 15 Jan) |
Cycle C (16 Jan to 17 March) |
|---|---|---|---|
|
| |||
| Anthropometrics documented on admission | |||
| At least MUAC | 1000/1026 (97.5) | 1308/1340 (97.6) | 2157/2219 (97.2) |
| At least weight | 1022/1026 (99.6) | 1331/1340 (99.3) | 2207/2219 (99.5) |
| At least height | 1003/1026 (97.8) | 1314/1340 (98.1) | 2189/2219 (98.6) |
| All MUAC, weight and height | 993/1026 (96.8) | 1305/1340 (97.4) | 2155/2219 (97.1) |
| SAM documented by admissiona | 44/88 (50.0) | 58/131 (44.3) | 94/199 (47.2) |
| HIV status documented on dischargeb | 36/44 (81.8) | 50/58 (86.2) | 84/94 (89.4) |
| Blood glucose documented within 24 hrs of admissionb | 18/44 (40.9) | 20/58 (34.5) | 59/94 (62.8)d |
| Proteinuria assessed within 48 hrs of admissionc | 1/3 (33.3) | 1/6 (16.7) | 5/8 (62.5) |
a
Only for those with SAM based on anthropometrics.
b
Only for those with SAM documented by admission.
c
Only for those with 3+ oedema. dp<0.05 by χ2 test comparing outcome of Cycle B or C with Cycle A.
d
Outcome measures are patient-centred experiences. Process measures describe steps in a system performing as planned. Balance measures are unintended consequences in the system.